Scrip 100: What It Takes To Sell $724bn-Worth Of Drugs
This article was originally published in Scrip
Executive Summary
The Scrip 100 is a story of fallers and risers and a changing helicopter view of the pharmaceutical industry. Data alone cannot predict individual transactions or the fates of particular pharmaceutical products. However, they do paint a clear picture of the nature of the industry and the commercial environment that companies face.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.